For lives unlimited
A global challenge
Estimates suggest that more than 160,000 people globally live with cystic fibrosis. It is a life-threatening disease that can significantly impair a patient’s quality of life and reduce longevity.
Modern diagnostics and therapeutics have extended the life expectancy of many cystic fibrosis sufferers substantially the last decades.
Call to action on CFTR
Next-generation DNA testing plays a core role in diagnosing cystic fibrosis and in screening future parents for the cystic fibrosis transmembrane conductance regulator (CFTR) mutations associated with the disease. To have cystic fibrosis, a child must inherit one copy of the CFTR gene mutation from each parent.
Information with impact
More than 2,000 CFTR gene mutations and variants are known. The vast majority of these have a population frequency of less than 0.1 percent and also vary widely across geographical areas and ethnic populations.
Genetic testing identifies CFTR mutations, enabling clinicians to confirm disease quickly in newborn children and ensure rapid treatment. Diagnosis at the prenatal stage helps prepare carrier couples already during pregnancy.
Carrier testing for future parents, including those with a known carrier partner, can provide important information for family planning decisions.
Cover your every testing need
Our genetic screening solutions for cystic fibrosis cover all your testing needs.
CFTR gene mutations vary widely across geographical areas and ethnic populations. At Devyser we have developed a portfolio of cystic fibrosis DNA screening solutions to cover this broad spectrum of need.
Our tests capture all mutations, regardless of geographical region or ethnicity. Their integrated user-friendly software enables routine simplicity in both first-line screening and second-level follow-up.
Prenatal and neonatal needs met
Devyser provides carrier tests for relatives of an affected person, or for those whose partners are known carriers. Our solutions also support prenatal diagnosis for carrier couples and population-based screening of newborn babies to enable rapid treatment.
Fast handling with ease of use
The tests are fast and easy to use. The CE-IVD solution is end-to-end – from sample to result. This saves time, is easy to implement, and is simple to replicate.
A short handling time of 45 minutes increases lab productivity, freeing up technicians to run more tests in a given time frame.
Insight and inspiration
News | January 17, 2024
Devyser Genomic Laboratories signs first commercial agreement
Devyser Genomic Laboratories, Devyser's US-based CLIA-certified laboratory, has signed its first commercial agreement with UK based diagnostics company Cyted.Find out more
News | January 15, 2024Devyser wins tender for cystic fibrosis in Italy
News | Jan 08, 2024Devyser signs in vitro diagnostic agreement with Illumina to broaden access to its tests
News | December 12, 2023Devyser wins tender for non-invasive fetal RHD testing in Wales